Emory University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).

1,208 total trials 208 currently recruiting 767 completed early-phase tilt top decile by trial count

Emory University: 1,208 sponsored US clinical trials, 208 recruiting.

Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.

Top-decile sponsor footprint

Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,208 total, page 24 of 25

TERMINATED

NIRS Monitoring in the Ambulatory Single Ventricle Patient

NCT00166218

TERMINATED

Quality of Life in Patients Post Radiofrequency Ablation

NCT00165997

COMPLETED NA

Safety and Effectiveness of Computer Screening for Intimate Partner Violence

NCT00166062

COMPLETED

Mental Health Symptoms and Intimate Partner Violence

NCT00166075

COMPLETED

Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy

NCT00165984

TERMINATED

Critical Congenital Heart Defect (CHD) Outcomes in Children

NCT00208689

COMPLETED NA

Recovery From General Anesthesia

NCT00165971

COMPLETED

Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI

NCT00166179

COMPLETED NA

Muscle Relaxation Therapy With Odorant Cue

NCT00208910

COMPLETED NA

Effect of Cola on Urinary Stone Risk Factors

NCT00289120

TERMINATED

Terminal Graft Failure

NCT00208884

COMPLETED Phase 4

A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

NCT00208819

COMPLETED NA

Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)

NCT00231309

TERMINATED Phase 2

Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease

NCT00209014

TERMINATED NA

Efficacy of Acupuncture for Hot Flashes in Women Treated With Hormonal Therapy for Breast Cancer

NCT00209001

COMPLETED NA

Cardiopulmonary Circuits in the Pediatric Population

NCT00208728

COMPLETED Phase 1

Effect of a Fatty Meal on Endoscopic Retrograde Cholangiopancreatography (ERCP)

NCT00124202

COMPLETED NA

A Randomized Controlled Trial to Promote Physician-Patient Discussion of Prostate Cancer Screening

NCT00208988

TERMINATED NA

Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors

NCT00966498

COMPLETED Phase 1

Effects of Hemodialysis on the Sleep/Wake Cycle

NCT00460863

COMPLETED NA

The Effects of Cool Dialysate on the Sleep/Wake Cycle in Patients on Chronic Hemodialysis - "The Sleep Cool Study"

NCT00218790

COMPLETED Phase 4

Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.

NCT00208715

COMPLETED

Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program)

NCT00590005

COMPLETED

Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients

NCT00379418

COMPLETED Phase 1

Mental Imagery to Reduce Motor Deficits in Stroke

NCT00379392

TERMINATED NA

Outcomes in Pediatric Heart Transplant Recipients Receiving Cellcept

NCT00166153

COMPLETED

Heparin Responses in Pediatric Patients Undergoing Cardiopulmonary Bypass.

NCT00166140

COMPLETED Phase 1

S.T.A.R.S.: Sistas Talking About Real Solutions

NCT01028157

TERMINATED Phase 2

A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF

NCT00208949

COMPLETED

NIRS in Neonatal Cardiac Surgery

NCT00166101

COMPLETED Phase 2

Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression

NCT00133809

TERMINATED Phase 2

Endothelial Hyperpolarization in Humans

NCT00166166

TERMINATED Phase 2

Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab

NCT00208975

COMPLETED Phase 4

Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder

NCT00208741

COMPLETED NA

HORIZONS HIV Intervention

NCT00633906

COMPLETED Phase 4

Depression, Epinephrine, and Platelet Function

NCT00166114

COMPLETED NA

Sensorimotor Gating in Schizophrenia

NCT00561561

COMPLETED NA

Psychoeducational Intervention for ICD Patients (PEACE)

NCT00146679

COMPLETED NA

Fear Potentiation and Fear Inhibition in Posttraumatic Stress Disorder

NCT00209040

COMPLETED

Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy

NCT00021866

COMPLETED NA

Recovery of Visual Acuity in People With Vestibular Deficits

NCT00411216

COMPLETED

Adult Congenital Heart Disease Surgery

NCT00446160

COMPLETED

Treatment of Reduced Heart Rate Variability Associated With Major Depression With Electroconvulsive Therapy

NCT00209066

COMPLETED Phase 2

Allogeneic Cell Therapy for Adults With Hematologic Malignancies

NCT00208962

COMPLETED Phase 2

Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer

NCT00003551

COMPLETED Phase 2

Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies

NCT00208923

COMPLETED

ADPKD Cohort Study

NCT02084849

COMPLETED NA

Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?

NCT00208897

COMPLETED

Effects of Beta-adrenergic in Adults w/Transposition of Great Arteries on Systemic Ventricular Function

NCT00313352

COMPLETED Phase 2

Diet/Growth Factor Mechanisms of Gut Adaptation

NCT00067860

← Previous Page 24 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 154
Phase 2 190
Phase 3 36
Phase 4 134

What is open in the Emory University pipeline

208 recruiting of 1,208 indexed (17% open); 767 completed (63%).

Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top condition: Depression (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Emory University: open-pipeline peers nationwide

Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Emory UniversityNorthwestern UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBaylor Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Hunter College of City University of New YorkOchsner Health System
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,208 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Emory University page

1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.

  • 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.